EGFR and neoplasm: In a TATTON study, a phase Ib trial, MET-amplified, and EGFR-mutant patients were treated with osimertinib plus savolitinib showing an acceptable risk-benefit profile and encouraging anti-tumor activity of the combination (objective partial responses in 48% of patients) [69].